A Carlsson

Summary

Country: Sweden

Publications

  1. ncbi Adaptive properties and heterogeneity of dopamine D(2) receptors - pharmacological implications
    Arvid Carlsson
    Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Brain Res Rev 58:374-8. 2008
  2. ncbi A dopaminergic deficit hypothesis of schizophrenia: the path to discovery
    Arvid Carlsson
    Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Dialogues Clin Neurosci 8:137-42. 2006
  3. ncbi The neurochemical circuitry of schizophrenia
    A Carlsson
    Department of Pharmacology, University of Goteborg, Sweden
    Pharmacopsychiatry 39:S10-4. 2006
  4. ncbi Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems
    A Carlsson
    Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden
    J Neural Transm 109:777-87. 2002
  5. ncbi A paradigm shift in brain research
    A Carlsson
    Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden
    Science 294:1021-4. 2001
  6. ncbi Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence
    A Carlsson
    Institute of Physiology and Pharmacology, University of Goteborg, Goteborg, Sweden
    Annu Rev Pharmacol Toxicol 41:237-60. 2001
  7. ncbi Network interactions in schizophrenia - therapeutic implications
    A Carlsson
    Department of Pharmacology, University of Goteborg, Box 431, SE 40530, Goteborg, Sweden
    Brain Res Brain Res Rev 31:342-9. 2000
  8. ncbi MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride
    P Martin
    Department of Pharmacology, Goteborg University, Sweden
    Eur J Pharmacol 335:107-16. 1997
  9. ncbi Neurotransmitter interactions in schizophrenia-therapeutic implications
    A Carlsson
    Department of Pharmacology, University of Goteborg, Sweden
    Eur Arch Psychiatry Clin Neurosci 249:37-43. 1999
  10. ncbi An improved HPLC-electrochemical detection method for measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid
    B Fornstedt
    Department of Pharmacology, University of Goteborg, Sweden
    J Neurochem 54:578-86. 1990

Collaborators

Detail Information

Publications20

  1. ncbi Adaptive properties and heterogeneity of dopamine D(2) receptors - pharmacological implications
    Arvid Carlsson
    Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Brain Res Rev 58:374-8. 2008
    ..For example, the application of this dichotomy appears to shed new light on the various subgroups of antipsychotic drugs and the mechanisms underlying their different profiles...
  2. ncbi A dopaminergic deficit hypothesis of schizophrenia: the path to discovery
    Arvid Carlsson
    Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Dialogues Clin Neurosci 8:137-42. 2006
    ....
  3. ncbi The neurochemical circuitry of schizophrenia
    A Carlsson
    Department of Pharmacology, University of Goteborg, Sweden
    Pharmacopsychiatry 39:S10-4. 2006
    ..Those models help us to understand the action of antipsychotic medications...
  4. ncbi Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems
    A Carlsson
    Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden
    J Neural Transm 109:777-87. 2002
  5. ncbi A paradigm shift in brain research
    A Carlsson
    Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden
    Science 294:1021-4. 2001
    ..Moreover, such tools sometimes turned out to be useful as therapeutic agents. Thus for the first time, a variety of disorders in the central nervous system could be treated effectively...
  6. ncbi Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence
    A Carlsson
    Institute of Physiology and Pharmacology, University of Goteborg, Goteborg, Sweden
    Annu Rev Pharmacol Toxicol 41:237-60. 2001
    ..Nevertheless, a precise identification of neurotransmitter aberrations in schizophrenia will probably provide clues for a better understanding of the disease and for the development of new treatment and prevention strategies...
  7. ncbi Network interactions in schizophrenia - therapeutic implications
    A Carlsson
    Department of Pharmacology, University of Goteborg, Box 431, SE 40530, Goteborg, Sweden
    Brain Res Brain Res Rev 31:342-9. 2000
    ..From a therapeutic perspective, several ongoing and forthcoming clinical trials, using drugs acting on dopaminergic, serotonergic and glutamatergic receptors, give rise to optimism...
  8. ncbi MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride
    P Martin
    Department of Pharmacology, Goteborg University, Sweden
    Eur J Pharmacol 335:107-16. 1997
    ..Ongoing clinical studies will hopefully give the answers in the near future...
  9. ncbi Neurotransmitter interactions in schizophrenia-therapeutic implications
    A Carlsson
    Department of Pharmacology, University of Goteborg, Sweden
    Eur Arch Psychiatry Clin Neurosci 249:37-43. 1999
    ..In a longer perspective, drugs interfering with glutamate function via different mechanisms may also turn out to be useful, especially in the control of negative symptoms...
  10. ncbi An improved HPLC-electrochemical detection method for measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid
    B Fornstedt
    Department of Pharmacology, University of Goteborg, Sweden
    J Neurochem 54:578-86. 1990
    ..The products generated during catechol autoxidation, including quinones and reduced forms of oxygen, are known to be potentially cytotoxic...
  11. ncbi A behavioural pattern analysis of hypoglutamatergic mice--effects of four different antipsychotic agents
    M Nilsson
    Department of Pharmacology, Institute of Physiology and Pharmacology, Goteborg University, Sweden
    J Neural Transm 108:1181-96. 2001
    ..Haloperidol was unable to affect the monotonous behaviour induced by MK-801, while risperidone, clozapine and M100907 produced movement patterns of high intricacy...
  12. ncbi Crucial role of the accumbens nucleus in the neurotransmitter interactions regulating motor control in mice
    A Svensson
    Department of Pharmacology, University of Goteborg, Sweden
    J Neural Transm Gen Sect 101:127-48. 1995
    ..Both glutamatergic, muscarine cholinergic, dopaminergic and alpha-adrenergic systems are involved in the control of motor functions in the accumbens nucleus...
  13. ncbi A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment
    B Fornstedt
    Department of Pharmacology, University of Goteborg, Sweden
    J Neural Transm 76:155-61. 1989
    ..Only small changes in the levels of the 5-S-cysteinyl adducts of DOPAC and 3,4-dihydroxyphenylalanine (DOPA) were found...
  14. ncbi In vivo dopamine (DA) receptor binding and behavioural effects of the putative DA autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 in rats with a unilateral nigral 6-OH-DA lesion
    M Hajos
    Department of Pharmacology, University of Goteborg, Sweden
    Exp Brain Res 70:577-84. 1988
    ..The implications of the present findings are discussed with particular reference to DA receptor sensitivity and adaptational phenomena...
  15. ncbi In vivo autoxidation of dopamine in guinea pig striatum increases with age
    B Fornstedt
    Department of Pharmacology, University of Goteborg, Sweden
    J Neurochem 55:655-9. 1990
    ..In contrast, the concentration of DOPAC increased with age: The DOPAC level in the 3-year-old animals was 153% of the level in the 2-week-old animals and 116% of the level in the 2-month-old animals.(ABSTRACT TRUNCATED AT 250 WORDS)..
  16. ncbi In vivo activity of tyrosine hydroxylase in rat adrenal glands following administration of quinpirole and dopamine
    M Kujacic
    Department of Pharmacology, University of Goteborg, Sweden
    Eur J Pharmacol 278:9-15. 1995
    ..The data support the view that stimulation of peripherally located dopamine D2-like receptors can enhance the rate of adrenal catecholamine synthesis by stimulating the activity of tyrosine hydroxylase...
  17. ncbi A half-century of neurotransmitter research: impact on neurology and psychiatry. Nobel lecture
    A Carlsson
    Department of Pharmacology, University of Gothenburg, Sweden
    Biosci Rep 21:691-710. 2001
    ..The effect that research on dopamine and other neutro trasmitters has on disciplines like neurology and psychiatry is described...
  18. ncbi Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis
    C A Tamminga
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland 21247, USA
    Curr Drug Targets CNS Neurol Disord 1:141-7. 2002
    ..One of them, aripiprazole, is nearing approval for marketing. With partial dopamine agonist treatment, advantages should accrue to schizophrenia treatment in the areas of affect control and cognitive performance...
  19. ncbi Schizophrenia: from dopamine to glutamate and back
    M L Carlsson
    Institute of Clinical Neuroscience, Neuropsychiatric Research Unit, Goteborg University, Sweden
    Curr Med Chem 11:267-77. 2004
    ....
  20. ncbi Identify the specific role of regional changes for the complex symptoms of schizophrenia
    F Tretter
    Pharmacopsychiatry 39:S1-2. 2006